Gut biofilms: real science, unsupported supplements
The part that is real, stated at its strongest
Biofilm biology is not fringe. It is established microbiology and established medicine. Bacteria routinely form structured communities embedded in a self-produced matrix that makes them dramatically more resistant to antibiotics and to immune clearance. That is why dental plaque, catheter-associated infections, prosthetic joint infections, chronic wounds and the airway infections in cystic fibrosis are so hard to treat. None of that is disputed.
The gut-specific evidence took a real step forward in 2021. Baumgartner and colleagues, publishing in Gastroenterology, assessed 1,426 patients across two European university endoscopy centres. During routine colonoscopy they found yellow-green layers adhering to the mucosa of the ileum and right colon, which survived standard polyethylene glycol bowel preparation. These were present in close to two-thirds of patients with irritable bowel syndrome and about a third of patients with ulcerative colitis, far more often than in people without those diagnoses.
They were not just visually present. They were associated with a measurable microbial signature, overgrowth of Escherichia coli and Ruminococcus gnavus, and with increased faecal bile acid excretion. Gastroenterology has since published a review specifically on gastrointestinal biofilms, their endoscopic detection and possible therapeutic strategies. This is an active, credible research area, not a wellness invention.
The part the marketing skips
An association found at colonoscopy establishes three things and leaves the important ones open.
- It does not establish causation. The biofilms may drive symptoms, may be a consequence of the same disturbed environment that drives symptoms, or may be a bystander. The bile acid finding is genuinely interesting precisely because it is compatible with all three.
- It does not establish that removal helps. Nobody has run the trial that removes biofilms and measures whether patients feel better. Until that exists, "you have a biofilm" and "removing your biofilm will fix you" are separate claims with separate evidence requirements, and only one of them has any.
- It gives you nothing you can act on at home. These were seen through an endoscope. There is no stool test, no symptom checklist and no questionnaire that tells you whether you have one.
What the biofilm disruptor supplements actually rest on
The common protocol ingredients are N-acetylcysteine, serrapeptase, nattokinase, EDTA, lumbrokinase and various proprietary enzyme blends, usually sold as a two-to-four week "phase" ahead of an antimicrobial phase.
The published support for them is laboratory work, and it is real laboratory work. Serrapeptase has documented anti-biofilm activity against Escherichia coli curli fibres, and against Staphylococcus aureus and Pseudomonas aeruginosa. N-acetylcysteine disrupts the extracellular matrix that holds biofilms together and improves antimicrobial penetration in vitro. These findings are not fabricated.
They are simply about a different question. Disrupting a biofilm on a catheter in a dish and improving somebody's bloating are separated by a chain of assumptions, each of which has to hold: oral survival through stomach acid, retained enzymatic activity through the small intestine, arrival at the right mucosal site, sufficient local concentration, actual disruption in that environment, and a clinical benefit that follows. Not one link of that chain has been demonstrated for gut symptoms in a properly designed human trial.
Notice also what the 2021 study implies about potency. These biofilms withstood a full PEG bowel prep, which is about as aggressive a flush as the colon ever receives. A capsule is being asked to do what that could not.
Where this could honestly go
We are not arguing that gut biofilms are nonsense. That would be the mirror-image error. The most likely future is that biofilms turn out to matter for a subgroup of people with IBS and IBD, that an actual intervention gets tested properly, and that the intervention looks nothing like a supplement stack you assemble yourself.
Until then, the honest position is: interesting finding, unresolved significance, no validated way to detect it outside endoscopy, and no evidence-based treatment. Paying several hundred pounds a year for a protocol built on that is buying a hypothesis at the price of a therapy.
What is worth doing instead
- Get the diagnosable things excluded: coeliac serology while still eating gluten, faecal calprotectin, and the rest of the tests that are actually worth it.
- Consider SIBO and intestinal methanogen overgrowth, which are real, testable, and treatable, and which the biofilm story is frequently sold alongside.
- Identify your own triggers by repeated, spaced testing rather than by elimination. That is slower and far more reliable, and it is what Minthe is built to do.
Minthe is a wellness and self-tracking tool, not a medical device. It does not diagnose or treat any condition and isn't a substitute for professional medical advice. If you have red-flag symptoms such as blood in your stool, unintentional weight loss, difficulty swallowing, persistent vomiting or a fever alongside gut symptoms, see a clinician rather than tracking them.
Sources
- Baumgartner M, et al. Mucosal biofilms are an endoscopic feature of irritable bowel syndrome and ulcerative colitis. Gastroenterology, 2021;161(4):1245-1256.
- Gastrointestinal biofilms: endoscopic detection, disease relevance, and therapeutic strategies. Gastroenterology, 2024.
- Serrapeptase eliminates Escherichia coli biofilms by targeting curli fibers, lipopolysaccharides, and phosphate metabolism. In vitro study.
Frequently asked
Are gut biofilms real?
Yes, and the evidence is stronger than sceptics often assume. A 2021 study in Gastroenterology examined 1,426 patients at two European university endoscopy centres and found endoscopically visible biofilms adhering to the ileal and right-colonic mucosa in close to two-thirds of patients with irritable bowel syndrome and about a third of patients with ulcerative colitis, far more often than in people without those conditions. They were associated with overgrowth of Escherichia coli and Ruminococcus gnavus and with increased faecal bile acid excretion.
Do biofilm disruptor supplements work?
There is no good human evidence that they do. The marketing rests on laboratory work: N-acetylcysteine, serrapeptase, nattokinase and EDTA can all disrupt bacterial biofilms in a dish, on catheters, and against organisms like Staphylococcus aureus and Pseudomonas aeruginosa. That is a very different claim from reducing gut symptoms in a person. Adequately powered randomised trials in people with gut complaints do not exist.
Why is in vitro evidence not enough?
Because the bar is low and the journey is long. Many substances disrupt biofilms in a dish, including ones you would never swallow. To matter clinically, a compound has to survive stomach acid, stay active through the small intestine, reach the specific mucosal site at a sufficient concentration, actually remove the biofilm there, and then produce a symptom improvement the person notices. Each of those steps is an assumption, and none has been demonstrated for these supplements.
If I have IBS, do I have a biofilm?
You might, on the 2021 figures, but you cannot know without a colonoscopy, and it would not change your treatment if you did. The study found an association at endoscopy. It did not establish that the biofilms cause the symptoms rather than resulting from the same underlying disturbance, and it did not test whether removing them helps.
So what should I do instead?
Work on the things with actual evidence behind them: get coeliac disease and inflammatory disease excluded properly, identify your own trigger foods by repeated testing rather than elimination, and treat conditions that are diagnosable and treatable such as SIBO, bile acid malabsorption, and pelvic floor dysfunction. Biofilm research may eventually produce a real treatment. It has not yet, and paying for the protocol now is buying a hypothesis.